Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth Analysis, By Treatment(Meditation, Stem Cell Therapy, Others.), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, diagnostics laboratories), By Region - Industry Forecast 2024-2031

Amyotrophic Lateral Sclerosis Treatment Market Driver

• Global amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the market during the forecast period.

Amyotrophic Lateral Sclerosis Treatment Market Restraint

• High cost of treatment, less awareness about amyotrophic lateral sclerosis diseases, and limited availability of treatment option are likely to hamper the market during the forecast period. Amyotrophic lateral sclerosis is so rare that treatment can be prohibitively expensive. Edaravone is a common drug or active ingredient used to treat ALS because it aids in the elimination of free radicals that cause neuron damage. This drug can cost around $145,000 per year. With other costs such as hospital bills, the entire treatment could cost around $200,000. Furthermore, there is no guarantee that such treatments will improve a patient's condition. As a result, even after spending thousands of dollars, very low survival rates can be a significant setback in the growth of the respective market.